Page last updated: 2024-11-13

dora-22

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

DORA-22: an orexin receptor antagonist; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID25126515
CHEMBL ID3655675
SCHEMBL ID1716753
MeSH IDM0585535

Synonyms (14)

Synonym
methanone, ((2r,5r)-5-(((5-fluoro-2-pyridinyl)oxy)methyl)-2-methyl-1-piperidinyl)(5-fluoro-2-(2-pyrimidinyl)phenyl)-
dora22
dora 22
1088991-95-0
dora-22
us8569311, 1-19
bdbm104702
SCHEMBL1716753
CHEMBL3655675
DTXSID10148765
EX-A4905
(5-fluoro-2-(pyrimidin-2-yl)phenyl)((2r,5r)-5-(((5-fluoropyridin-2-yl)oxy)methyl)-2-methylpiperidin-1-yl)methanone
[(2r,5r)-5-[(5-fluoropyridin-2-yl)oxymethyl]-2-methylpiperidin-1-yl]-(5-fluoro-2-pyrimidin-2-ylphenyl)methanone
AKOS040758766

Research Excerpts

Dosage Studied

ExcerptRelevanceReference
"Active-phase dosing of DORA-22 induced consistent effects on sleep architecture in mice, rats, dogs, and rhesus monkeys; attenuation of active wake was accompanied by increases in both non-rapid eye movement (NREM) and rapid eye movement (REM) sleep."( Differential sleep-promoting effects of dual orexin receptor antagonists and GABAA receptor modulators.
Coleman, PJ; Fox, SV; Garson, SL; Gotter, AL; Kuduk, SD; McDonald, T; Munden, RL; Renger, JJ; Stevens, J; Tannenbaum, PL; Tye, SJ; Uslaner, JM; Winrow, CJ; Yao, L, 2014
)
0.71
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (9)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's7 (77.78)24.3611
2020's2 (22.22)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 38.23

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index38.23 (24.57)
Research Supply Index2.30 (2.92)
Research Growth Index4.55 (4.65)
Search Engine Demand Index47.77 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (38.23)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other9 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]